背景:在这项研究中,我们在大鼠模型中研究了基质金属蛋白酶-1(MMP-1)对皮肤伤口愈合的影响。
方法:本研究包括16只Sprague-Dawley雄性大鼠。用4.4mm的冲头在每只大鼠的背侧区域上产生四个全厚度皮肤伤口。将大鼠随机分为两组。每天一次腹膜内施用MMP-1和盐水,持续7天。活检是在4号从单独的伤口上取下的,Seven,实验的第14天和第21天。淋巴细胞反应,血管增生,成纤维细胞增殖,上皮增生,异物反应,溃疡形成,急性炎症,在组织病理学上比较各组瘢痕疙瘩瘢痕形成和增生性瘢痕形成。
结果:在我们的研究中,与对照组相比,MMP-1组第14天的上皮增生明显高于对照组(p<0.05)。第4天和第21天的淋巴细胞反应,第4天血管增生,第4天和第7天的成纤维细胞增殖,第4天的急性炎症和第7天的肥厚性瘢痕形成,14日,第21天MMP-1组显著低于对照组(p<0.05)。与其他参数相比,差异无统计学意义(p>0.05)。
结论:MMP-1可改善皮肤上皮增生的创面愈合过程,减少瘢痕形成。因此,MMP-1可以潜在地用作预防或治疗增生性瘢痕的有效的抗纤维化剂。
■本期刊要求作者为每篇文章分配一定程度的证据。对于这些循证医学评级的完整描述,请参阅目录或在线作者说明www。springer.com/00266.
In this study, we investigated the effect of matrix metalloproteinase-1 (MMP-1) on wound healing on skin in a model produced in rats.
Sixteen Sprague-Dawley male rats were included in the study. The four full-thickness skin wound was created on the dorsal area of each rat with 4.4 mm punch. The rats were randomly divided into two groups. MMP-1 and saline were administered intraperitoneally once daily for 7 days. The biopsies were taken from the separate wounds on the 4th, 7th, 14th and 21st days of the experiment. The lymphocytic response, vascular proliferation, fibroblast proliferation, epithelial hyperplasia, foreign body reaction, ulcer formation, acute inflammation, keloid scar formation and hypertrophic scar formation were compared in each group in histopathologically.
In our study, epithelial hyperplasia on 14th day was significantly higher in the MMP-1 group compared to the control group (p < 0.05). The lymphocytic response on 4th and 21th days, the vascular proliferation on 4th day, the fibroblast proliferation on 4th and 7th days, the acute inflammation on 4th day and the hypertrophic scar formation on 7th, 14th, 21st days were significantly lower in the MMP-1 group compared to the control group (p < 0.05). No statistically significant difference was found in comparison with other parameters (p > 0.05).
MMP-1 improves the wound-healing process of skin with higher epithelial hyperplasia and reduces scar formation in the animal model. Therefore, MMP-1 can potentially be used as an effective anti-fibrogenic agent for preventing or treating the hypertrophic scar.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .